The Effct of Chitooligosaccharide on Immune Function in Healthy Adults

This study has been completed.
Information provided by:
Eulji University Hospital Identifier:
First received: May 2, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted

Functional properties of chitooligosaccharides have been studied for antitumor activity, immunostimulating effects, antimicrobial activity, free radical scavening activity, adn angiotensin I converting enzyme inhibitory activity. Recent in vitro, and in vivo toxicity and absorbability studies have demonstrated that chitooligosaccharides have high absorbability and are essentially non-toxic. In the present study, we prepared a chitooligosaccharide with high absorbability and evaluated its effects on activation of immune function and cardiovascular funciton(lipid, atrial stiffness, etc) in healthy adults.

This study was a 8-week, randomized, double-blind clinical trial. The 30 volunteers were divided into a control group(n=10), half dose chitooligosaccaride(FACOSTM) intake group(n=10), and full dose FACOS intake group(n=10). Peripheral blood mononuclear cells(PBMCs) were isolated and cultured in 12 well plate for 48 hours. Cytokine production by PBMCs pre- and postintervention were measured simultaneously after stimulation with lipopolysaccaride.

Condition Intervention Phase
Drug: FACOS (functional food)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Further study details as provided by Eulji University Hospital:


Ages Eligible for Study:   20 Years to 50 Years
Genders Eligible for Study:   Both

Inclusion Criteria:

  • healthy adults(the ages between 20~50 year)

Exclusion Criteria:

  • food allergy and allergy skin disease
  • severe liver and kidney disease
  • pregnant, lactating women
  • cancer, stroke, etc.
  Contacts and Locations
Please refer to this study by its identifier: NCT00468962

Sponsors and Collaborators
Eulji University Hospital
Principal Investigator: Hee-Jeong Choi, MD, Ph.D Eulji University Hospital
  More Information

No publications provided Identifier: NCT00468962     History of Changes
Other Study ID Numbers: 07-05
Study First Received: May 2, 2007
Last Updated: May 2, 2007
Health Authority: Korea: Food and Drug Administration processed this record on April 16, 2014